Kantarjian et al53 assessed the efficacy and protection of dasatinib, as in comparison with imatinib, for the main-line treatment of CML-CP. Five hundred and nineteen individuals with recently diagnosed CML-CP ended up randomly assigned to receive dasatinib at a dose of one hundred mg the moment day by day (259 https://richardi207zfi1.wikitron.com/user